We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Ultra-Portable POC Molecular Diagnostics System to Instantly Detect Infectious Diseases

By LabMedica International staff writers
Posted on 02 Feb 2024

Infectious diseases pose a significant threat to human health and have a substantial economic impact globally. More...

Timely and accurate identification of pathogens is key for prompt treatment, improved patient outcomes, and halting the spread of diseases. Traditional pathogen detection methods are usually conducted in well-equipped clinical labs, relying on advanced equipment and specialized staff. Furthermore, pre-analytical steps such as lengthy transportation can skew results and extend turnaround times (TAT), hindering effective control of infectious diseases, especially in areas with limited resources. Now, a rapid RT-PCR platform being developed to provide highly accurate, rapid, and affordable diagnoses of infectious diseases at point-of-care and near-patient settings could enable immediate treatment initiation and curtail potential disease transmission.

Novel Microdevices (Baltimore, MD, US) is advancing its affordable, portable, rapid, multiplex, and user-friendly PCR testing solution for infectious diseases. This innovative technology simplifies complex scientific processes, typically carried out in high-complexity labs, into a compact device. Point-of-care diagnostics offered by the Novel Dx device allow for immediate results, enabling prompt action instead of the extended waiting times associated with traditional laboratory tests. The Novel Dx device employs Nucleic Acid Amplification Techniques (NAAT), which is the same method used in clinical reference laboratories, to detect the genetic material of pathogens.

The Novel Dx molecular testing platform utilizes polymerase chain reaction (PCR) technology in a disposable cartridge. The patient's sample is added to this cartridge, which is then inserted into the Novel Dx system. The system analyzes genetic sequences to identify diseases and detect genetic mutations that may make bacteria resistant to antibiotics. Novel Dx is capable of providing lab-quality results in less than 15 minutes, allowing patients to be tested, diagnosed, and treated all within a single visit, thus eliminating the wait for results from more complex labs. Designed for portability and weighing just four pounds, the Novel Dx diagnostic tool is battery-operated, making it especially suitable for use in low-resource settings and low-and middle-income countries (LMICs).


Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Portable Electronic Pipette
Mini 96
Gold Member
Hematology Analyzer
Medonic M32B
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.